Merck (NYSE:MRK) has seen strong growth in its Oncology drug Keytruda, along with Vaccine Gardasil in the recent quarters. The company's Q2 results topped street estimates, led by a strong growth in these two drugs. We continue to believe that Merck's near term growth can largely be linked to the...
Merck (NYSE:MRK) has seen strong growth in its Oncology drug Keytruda, along with Vaccine Gardasil in the recent quarters. The company's Q2 results topped street estimates, led by a strong growth in these two drugs. We continue to believe that Merck's near term growth can largely be linked to the...
Share this Article
Recommended